Clinical and Experimental Nephrology

, Volume 11, Issue 3, pp 251–254

Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient

  • Osama Gheith
  • Adel Bakr
  • Ehab Wafa
  • Ashraf Fouda
  • Amgad El Agroudy
  • Ayman Refaie
  • Ahmed Donia
  • Alaa Sabry
  • Mohamed Sobh
  • Ahmed Shokeir
  • Mohamed Ghoneim
CASE REPORT

DOI: 10.1007/s10157-007-0470-y

Cite this article as:
Gheith, O., Bakr, A., Wafa, E. et al. Clin Exp Nephrol (2007) 11: 251. doi:10.1007/s10157-007-0470-y

Abstract

The incidence of Kaposi's sarcoma among recipients of solid organs is about 500 times the rate in the general population, suggesting a role for immunosuppression in its development. On the basis of these findings, we investigated the impact of sirolimus on cutaneous and disseminated visceral Kaposi's sarcoma in a renal-transplant recipient. The introduction of sirolimus in this patient allowed complete regression of Kaposi's sarcoma (cutaneous and visceral) with preservation of excellent renal function. Meanwhile, in view of the available observational reports, we think that sirolimus should be included in the standard treatment for Kaposi's sarcoma after transplantation, to permit remission of the sarcoma (both cutaneous and visceral) while preserving the renal function.

Key words

Sirolimus Renal transplant Malignancy 

Copyright information

© Japanese Society of Nephrology 2007

Authors and Affiliations

  • Osama Gheith
    • 1
  • Adel Bakr
    • 1
  • Ehab Wafa
    • 1
  • Ashraf Fouda
    • 1
  • Amgad El Agroudy
    • 1
  • Ayman Refaie
    • 1
  • Ahmed Donia
    • 1
  • Alaa Sabry
    • 1
  • Mohamed Sobh
    • 1
  • Ahmed Shokeir
    • 1
  • Mohamed Ghoneim
    • 1
  1. 1.Urology and Nephrology CenterMansoura UniversityGomhoria St. MansouraEgypt

Personalised recommendations